RT Journal Article
SR Electronic
T1 Predicting the Effectiveness of the Pfizer-BioNTech BNT162b2 Vaccine from SARS-CoV-2 Variants Neutralisation Data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.06.21263160
DO 10.1101/2021.09.06.21263160
A1 Volkov, Oleg
A1 Borozdenkova, Svetlana
A1 Gray, Alexander
YR 2021
UL http://medrxiv.org/content/early/2021/09/13/2021.09.06.21263160.abstract
AB Modelling frameworks for vaccine protection are sorely needed to fight the Covid-19 pandemic with vaccines. We propose such a framework for the BNT162b2 and potentially other vaccines. It identifies correlates of protection based on live SARS-CoV-2 variants neutralising antibody titres from vaccinated individuals. We applied it to predict vaccine effectiveness in overall populations and age subgroups. It was validated by predicting effectiveness against the B.1.167.2 (Delta) variant. The predictions, of 51.7% (34%, 69%) after one and of 88.6% (76%, 97%) after two vaccine doses, were close to the corresponding means, 49% and 85.4%, of observations in real-life effectiveness studies. We illustrate its applications to inform decisions, such as about the doses and timing of vaccine boosters.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and R code used for this paper are freely available starting on or before 14 Sep 2021. https://github.com/spockoyno/pfizer_biontech_vaccine_paper